Peptide-Conjugated Silver Nanoparticle for Autoantibody Recognition.

Area of Science:

• Nanotechnology
• Immunopathology
• Biomarker Discovery

Background:

• Autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) are implicated in demyelinating diseases.
• Early diagnosis of demyelinating diseases relies on accurate autoantibody detection.
• Novel sensing platforms are needed for sensitive and specific autoantibody detection.

Purpose of the Study:

• To develop and evaluate silver nanoparticles (AgNPs) as a sensing device for autoantibodies against MOG and MBP.
• To investigate the conjugation of MOG and MBP peptides onto AgNPs.
• To assess the recognition of autoantibodies by peptide-conjugated AgNPs.

Main Methods:

• Synthesis and characterization of AgNPs using AFM, XRD, DLS, and UV-Vis spectrophotometry.
• Peptide conjugation onto AgNPs and analysis of the conjugation process.
• Evaluation of autoantibody recognition using UV-Vis spectrophotometry, AFS, and colorimetric assays.

Main Results:

• Synthesized AgNPs exhibited spherical morphology, low polydispersity, and cubic crystal structure (29.3±3.0 nm).
• MBP peptide conjugation induced greater AgNP agglomeration than MOG peptide.
• Peptide-conjugated AgNPs efficiently bound autoantibodies, evidenced by spectral shifts and visible color changes.

Conclusions:

• MOG- and MBP-conjugated AgNPs show potential as a sensing platform for autoantibody detection.
• This nanoscale sensing approach offers promising implications for identifying diagnostic biomarkers in demyelination.
• Further development could lead to improved early diagnostic tools for demyelinating diseases.